Home > Insider Trading > Filing (0000950170-24-108233)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1593899	Atea Pharmaceuticals Inc.	AVIR	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1296995	Jean-Pierre Sommadossi	225 Franklin Street Suite 2100 Boston MA 02110	President, Ceo, And Chairman	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-09-17	33,941	$4.05	5,890,053	No	4	S	Indirect	Held by JPM Partners LLC
Common Stock	Disposition	2024-09-18	22,187	$4.03	5,867,866	No	4	S	Indirect	Held by JPM Partners LLC
Common Stock	Disposition	2024-09-19	1,841	$4.00	5,866,025	No	4	S	Indirect	Held by JPM Partners LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	Held by JPM Partners LLC
No	4	S	Indirect	Held by JPM Partners LLC
No	4	S	Indirect	Held by JPM Partners LLC

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	116,557	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.14. The Reporting Person undertakes to provide Atea Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.0975. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.01. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.